HIV

The REPRIEVE study finds statins cut heart events in HIV by lowering lipids, inflammation, and hypertension risk.

A session at CROI 2026 opened with questions on how glucagon-like peptide-1 receptor agonists could be used in HIV.

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for remission without therapy.

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to improve testing and treatment access.

New research shows that adherence to antiretroviral therapy and pre-exposure prophylaxis depends on a steady budget through PEPFAR and SNAP.

Posters presented during the Conference on Retroviruses and Opportunistic Infections 2026 highlight the safe use of tirzepatide in patients with HIV.

The first full day of CROI 2026 featured a lecture that outlined the next steps in treating and preventing HIV.

The conference, held in Denver, Colorado, promises presentations on breaking research and the future of prevention.

Medicare HIV cases are projected to double by 2035, with cumulative costs reaching $195.6 billion and creating critical challenges for federal funding.

The most-read content for HIV focused on funding cuts to HIV aid and research and satisfaction with telemedicine for HIV care.

Our top conference coverage of the year highlighted findings presented at CROI 2025, ACCC Spring, and EHA, among others.

The past year has seen multiple changes in the HIV space that have long-term effects when it comes to ending the epidemic.

Top content from CROI 2025 focused on COVID-19 and HIV, including the safety of a vaccine in people taking antiretroviral therapy.

Although a cure is likely still a ways off, continuing to pursue long-acting injectable treatments and PrEP is key to reducing cases of HIV.

Lenacapavir and cabotegravir are among the most important advancements in HIV prevention and treatment within the past 10 years.

The HIV chatbot was noninferior in increasing self-testing compared with the real-time support by human administrators.

Individuals told their absolute risk of HIV had higher interest in pre-exposure prophylaxis (PrEP) compared with those told relative risk.

Men who have sex with men (MSM) expressed interest in both monthly oral pills and injections every 6 months to prevent HIV.

Topline results find that single-tablet regimen of bictegravir/lenacapavir had noninferior efficacy when patients switched from multitablet regimens in HIV.

The efficacy of immune checkpoint inhibitors was found in patients with both HIV and non–small cell lung cancer (NSCLC), though more inclusion of people with HIV is needed in future studies.

Young and frequently incarcerated individuals living with HIV require discharge planning and post release support to maintain viral suppression outcomes.

Researchers found more local pharmacies than facilities that prescribed pre-exposure prophylaxis (PrEP) in areas of high case load.

The government should focus on keeping up the funding for HIV to continue to innovate in this space, potentially eliminating the virus altogether.

Opioids were more likely to be prescribed to Medicare beneficiaries living with HIV, which led to opioid use disorder (OUD).

Funding cuts for research intended to make treatment and cures available and accessible for patients with HIV could affect HIV care in the long term.